Antiphosphatidylethanolamine Antibodies: New Pieces to the P | 46344

Journal of Arthritis

ISSN - 2167-7921


Antiphosphatidylethanolamine Antibodies: New Pieces to the Puzzle of the Antiphospholipid Syndrome?

Caroline Zaratzian, Joris Zypinoglou, Pierre Emmanuel Morange and Nathalie Bardin

Objective: To show the contribution of antiphosphatidylethanolamine antibodies (aPE) screening in Antiphospholipid antibody syndrome (APS) diagnosis, especially in Antiphosphopholipid Syndrome (SNAPS) patients, based on litterature data.

Methods: A comprehensive literature review of English-language articles from January 1st 2000 to December 31th 2014 was performed using PudMed. Keywords used for the search were: seronegative antiphospholipid antibody OR phosphatidylethanolamine function, biosynthesis and physiological roles OR antiphosphatidylethanolamine antibody OR seronegative antiphospholipid syndrome.

Results: Although aPE was not included in the Sapporo criteria for the classification of APS, many studies described a significant association between aPE and the main clinical events of APS: thrombosis and obstetrical complications.

Conclusion: Because of aPL family’s heterogeneity, it appears necessary to look for non-criteria aPL in order to improve the diagnostic yield in APS, especially in patients with SNAPS. One of the most promising of this heterogeneous aPL family is aPE. Although these molecules may allow early detection of APS, their clinical relevance is still debatable and needs standardized aPE ELISA, in addition to well-designed clinical studies to confirm its diagnostic value, such as the association between recursion of thrombotic events and the presence of aPE.